VBL Therapeutics to Present Data from VB-201 and VB-111 at Prominent Cancer Research and Dermatology Medical Meetings

TEL AVIV, Israel--(BUSINESS WIRE)--Apr 13, 2010 - VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.

“We are pleased that these two esteemed medical meetings focused in the areas of dermatology and cancer have selected us to present data on both our proprietary Vascular Targeting System technology for the treatment of patients with advanced metastatic cancer and our Lecinoxoid class of oral anti-inflammatory agents that VBL pioneered for the treatment of inflammatory conditions such as psoriasis, rheumatoid arthritis and atherosclerosis,” said Professor Dror Harats, M.D., chief executive officer of VBL Therapeutics.

Phase 1 and pre-clinical data for VB-111 in advanced cancer will be presented at the American Association of Cancer Research's 101st Annual Meeting being held April 17-21, 2010 at the Walter E. Washington Convention Center in Washington, D.C. The two posters will be presented during the “Tumor Biology Sessions” on Monday, April 19 between 9 a.m. and 12 p.m. in exhibit hall A-C, in poster section 15.

Pre-clinical data for VB-201 in psoriasis will be presented at the Society for Investigative Dermatology's 70th Annual Meeting, being held May 5-8, 2010 at the Hilton Atlanta Hotel in Atlanta, Ga. The poster will be presented during the second poster session on Friday, May 7 from 11:15 a.m. to 1:15 p.m.

About VBL Therapeutics

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents and VB-201 is the lead candidate from this program, which has entered Phase 2 clinical development in patients with psoriasis. In addition, VBL has a proprietary Vascular Targeting System (VTS™) technology platform that has yielded VB-111, the first dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is expected to enter Phase 2 clinical trials in 2010. The company was founded in 2000 and is based in Tel Aviv, Israel. VBL has 55 granted patents and more than 115 patents pending. For more information on the company, please visit www.vblrx.com.

 

Contact: Pure Communications
Dan Budwick, 973-271-6085

 

 

Posted: April 2010

View comments

Hide
(web1)